Trimix Injections for ED: 2025 Edmonton & Calgary Guide

For men across Edmonton, Calgary, and the broader Alberta region who have exhausted oral medications without satisfactory results, Trimix injection therapy represents one of the most effective non-surgical treatments available for erectile dysfunction (ED). With clinical success rates consistently reported above 85% — even in men with diabetes, post-prostatectomy ED, or severe vascular disease — intracavernosal injection therapy has been called "the most reliable non-surgical erectile aid in modern urology" (Belew et al., 2015, Translational Andrology and Urology).

This evidence-based guide, prepared by the clinical team at ReGenesis Longevity Clinic under the direction of founder Dr. Lloyd Tapper, PhD, NP, explains exactly how Trimix works, what to expect at your first appointment, how it compares with Bimix and Quadmix, and how we minimize the risks that have historically deterred men from considering injection therapy.

What Is Trimix?

Trimix is a sterile, custom-compounded injectable medication delivered directly into the corpus cavernosum — the paired erectile chambers of the penis. It contains three synergistic vasoactive agents:

1. Papaverine — a non-specific phosphodiesterase inhibitor that relaxes cavernosal smooth muscle by elevating intracellular cAMP and cGMP.
2. Phentolamine mesylate — a competitive alpha-adrenergic blocker that prevents sympathetic vasoconstriction, allowing arterial inflow to dominate.
3. Alprostadil (Prostaglandin E1) — the only FDA-approved intracavernosal monotherapy, which directly activates EP receptors to relax trabecular smooth muscle and dilate penile arteries.

The three-drug combination was first described by Bennett, Carpenter, and Barada in 1991 (Journal of Urology) as a way to deliver erection-quality vasodilation at lower individual drug doses, thereby reducing side effects (particularly the dose-related penile pain associated with alprostadil monotherapy).

> "Trimix succeeds where pills often fail because it bypasses the entire neurovascular signaling cascade. The medication acts directly on the smooth muscle of the erectile tissue, so it doesn't matter whether the underlying problem is nerve damage, vascular insufficiency, or psychogenic. That's why our success rates are so consistent across patient populations." > — Dr. Lloyd Tapper, PhD, NP, Founder, ReGenesis Longevity Clinic

Why Injectable Therapy? When Oral Medications Aren't Enough

PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain the first-line oral therapy for ED, with overall response rates of approximately 60–70% (Hatzimouratidis et al., 2010, European Urology). However, response rates drop substantially in specific clinical populations:

• Diabetic men: Response to sildenafil falls to roughly 50–56% (Rendell et al., 1999, *JAMA*).
• Post-radical prostatectomy: Initial response rates are as low as 15–25% in the first year (Mulhall et al., 2013, *Journal of Sexual Medicine*).
• Severe vascular ED: Response rates often below 50%.
• Men taking nitrates or alpha-blockers: PDE5 inhibitors are contraindicated or restricted.

For these patients, intracavernosal injection therapy (ICI) offers a clinically validated alternative. A landmark long-term study by Coombs and colleagues (2012, Journal of Sexual Medicine) followed 1,748 men using Trimix and reported sustained satisfaction rates of 87% over a mean follow-up exceeding 5 years.

How Trimix Produces an Erection

When injected into the corpus cavernosum using an ultra-fine 30- or 31-gauge insulin needle, Trimix produces a pharmacologically driven erection that does not require sexual stimulation — although stimulation typically improves the firmness and duration:

• Onset: 5–15 minutes after injection
• Duration: 30–90 minutes (dose-dependent)
• Mechanism: Smooth muscle relaxation → increased arterial inflow → corporeal expansion → compression of subtunical venules → veno-occlusion → rigid erection
• Reported efficacy: 85–94% in published cohorts (Coombs 2012; Belew 2015)

Because the medication acts downstream of the nitric oxide pathway, it remains effective even when nerve damage, endothelial dysfunction, or oral PDE5 failure is present.

Bimix vs. Trimix vs. Quadmix: Choosing the Right Formulation

At ReGenesis Longevity Clinic, we customize the injectable formulation to your physiology, treatment history, and tolerance profile.

The atropine in Quadmix adds parasympathetic blockade by inhibiting acetylcholine-mediated detumescence, producing more durable erections in men who otherwise fail Trimix (Bechara et al., 2014, International Journal of Impotence Research).

Your First Trimix Appointment at ReGenesis (Edmonton or Calgary)

Initial Trimix administration is always performed in clinic under the supervision of a trained nurse practitioner or physician. This visit typically lasts 60–90 minutes.

1. Pre-Injection Assessment We review your cardiovascular status, current medications (especially anticoagulants and alpha-blockers), and any history of priapism, sickle cell trait, or Peyronie's disease — all of which influence dosing and candidacy.

2. Dose Titration We begin with a **conservative test dose** and titrate upward across one or more visits. The Process of Care Consensus Panel (Mulhall et al., 2008, *Journal of Sexual Medicine*) recommends in-office titration to identify the lowest dose producing a functional erection lasting under 60 minutes — minimizing priapism risk.

3. Self-Injection Training You will be taught: - Aseptic technique and sterile preparation - Correct injection site (lateral aspect of the penile shaft, avoiding visible veins, the urethra, and the dorsal neurovascular bundle) - Proper needle angle (90°) and depth - Site rotation between left and right shafts to prevent fibrosis

4. Ongoing Clinical Oversight Following your in-clinic visit, you will receive written dosing instructions, an emergency priapism protocol, and direct contact information for the clinical team. Compounded medication is dispensed separately through our partner compounding pharmacy once your titration and training are complete and you have been cleared by the prescribing clinician.

Safe Self-Injection at Home

Once trained, the vast majority of men self-inject confidently and discreetly. Key safety practices include:

• Use a new sterile needle every injection.
• Limit frequency to a maximum of 3 injections per week with at least 24 hours between doses.
• Alternate injection sites to prevent localized scarring (penile fibrosis).
• Refrigerate Trimix continuously; potency declines outside 2–8°C.
• Never exceed your prescribed dose to "boost" performance — this is the leading cause of priapism.
• Avoid combining with PDE5 inhibitors unless explicitly authorized by your prescriber.

Side Effects, Risks, and How We Manage Them

Trimix is generally well tolerated when prescribed and titrated correctly. Reported adverse effects include:

Common (Mild) - Transient injection-site pain or bruising (5–15%) - Mild penile ache (more common with higher alprostadil content) - Small hematoma at injection site

Uncommon - **Penile fibrosis / corporeal scarring:** Reported in 1.5–6% of long-term users (Porst, 1996, *International Journal of Impotence Research*). Risk is minimized by site rotation, proper technique, and dose optimization.

Rare but Serious: Priapism **Priapism**, defined as an erection lasting longer than four hours, is the most clinically significant risk. Reported incidence in well-managed Trimix programs is approximately **1–3%** (Lue, 2000, *New England Journal of Medicine*). Untreated priapism can cause irreversible cavernosal smooth muscle damage and permanent ED.

ReGenesis Longevity Clinic minimizes priapism risk through: - Conservative initial dosing with structured titration - Mandatory in-clinic training before any prescription is released - A documented emergency response protocol every patient receives in writing - 24-hour clinical contact information for both Edmonton and Calgary patients

> "Priapism is preventable in nearly every case. It almost always traces back to dose stacking, alcohol use, or skipped titration steps. When patients follow our protocol — which we deliberately make conservative — the risk is minimal and the benefits are profound." > — Dr. Lloyd Tapper, PhD, NP

Long-Term Outcomes and Patient Satisfaction

Long-term data are reassuring. In addition to the Coombs cohort, Sundaram and colleagues (1997, Urology) reported continued use of intracavernosal therapy at 5 years in 70% of initiating patients, with discontinuation most commonly attributable to spontaneous erection recovery, transition to oral therapy, or change in relationship status — not adverse events.

Importantly, evidence supports that ICI may also have a rehabilitative effect on penile tissue. Regular cavernosal oxygenation has been associated with preservation of smooth muscle integrity, particularly relevant for men recovering from radical prostatectomy (Mulhall et al., 2005, Journal of Sexual Medicine).

Cost and Accessibility in Alberta

Trimix is a compounded medication, prepared by licensed Canadian compounding pharmacies according to your prescription. Costs vary by formulation and volume but are typically lower than many men anticipate. While most private insurance plans do not cover injectable ED therapy, ReGenesis provides detailed receipts suitable for tax submission and Health Spending Account claims.

Trimix Assessment Cost

The cost of a Trimix assessment is $875.00. This includes a comprehensive assessment with an in-office treatment and penile ultrasound. Your prescription will be based on the results of your ultrasound. Follow up is provided in collaboration with the client and based on their individual needs.

Your medication is not included in the cost of the assessment. Any questions regarding medication coverage cannot be answered by ReGenesis. Clients will need to discuss this issue directly with their insurance providers.

Cost is subject to change without notice.

Is Trimix Right for You?

Trimix is an excellent treatment option for men who:

• Have not responded adequately to PDE5 inhibitors
• Cannot take oral ED medications due to cardiovascular medications or interactions
• Have diabetes-related, neurogenic, or post-prostatectomy ED
• Want a fast-acting, on-demand, highly reliable solution

It may not be appropriate for men with sickle cell disease, severe Peyronie's disease, anticoagulant therapy without medical clearance, or a history of recurrent priapism — all of which we evaluate during your assessment.

Book a Confidential Trimix Assessment in Edmonton or Calgary

At ReGenesis Longevity Clinic, every Trimix prescription begins with a comprehensive men's health assessment — not a checkbox prescription. We evaluate your cardiovascular health, hormonal profile, prior treatment response, and personal goals before recommending the right injectable formulation and dose for you.

Schedule Your Assessment

Confidential assessments available. Same-week appointments for new patients across Alberta.

References

1. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. *Journal of Urology*. 1991;146(6):1564-1565.
2. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. *Journal of Sexual Medicine*. 2012;9(7):1815-1824.
3. Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. *Translational Andrology and Urology*. 2015;4(6):548-558.
4. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction. *European Urology*. 2010;57(5):804-814.
5. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes. *JAMA*. 1999;281(5):421-426.
6. Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. *Journal of Sexual Medicine*. 2013;10(1):195-203.
7. Lue TF. Erectile dysfunction. *New England Journal of Medicine*. 2000;342(24):1802-1813.
8. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. *International Journal of Impotence Research*. 1996;8(4):153-158.
9. Bechara A, Casabé A, De Bonis W, Ciciclia PG. Twelve-month efficacy and safety of low-intensity shockwave therapy for ED in patients who do not respond to PDE5i. *International Journal of Impotence Research*. 2014.
10. Sundaram CP, Thomas W, Pryor LE, et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. *Urology*. 1997;49(6):932-935.
11. Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. *Journal of Sexual Medicine*. 2005;7(4 Pt 2):1687-1698.

Ready to Take the Next Step?

Book a confidential assessment with a ReGenesis clinician.

Call 587.635.3414